Literature DB >> 21057964

Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma.

Mireia Caralt1, Josep Martí, Javier Cortés, Constantino Fondevila, Itxarone Bilbao, Josep Fuster, Juan Carlos García-Valdecasas, Gonzalo Sapisochín, Joaquim Balsells, Ramón Charco.   

Abstract

BACKGROUND/
PURPOSE: The aim of this study was to analyze the outcome of patients undergoing hepatic resection for melanoma liver metastases.
METHODS: Patients undergoing liver resection for melanoma metastases at the Hospital Vall d'Hebron and Hospital Clinic, Barcelona, were reviewed. Selection criteria were: good performance status, feasibly complete and safe resection, and absence of visceral extrahepatic metastases.
RESULTS: Between 1994 and 2007, 14 liver resections were performed for melanoma liver metastases. The primary tumor was cutaneous in 8 patients and ocular in 6. Two patients underwent urgent liver surgery due to tumor bleeding. In these patients, complete melanoma staging was not performed and extrahepatic metastases were found during surgery or during the postoperative course. Six of 13 patients (46.2%) developed liver recurrence during follow-up. One- and 3-year actuarial patient survivals were 77 and 49%, respectively. Excluding the patients who underwent urgent liver surgery, the 1- and 3-year actuarial patient survivals in those with primary ocular and cutaneous melanoma were 83 and 56% and 80 and 60%, respectively.
CONCLUSIONS: Liver resection may be considered as part of oncosurgical treatment in patients with melanoma liver metastases, since prolonged survival was observed, albeit with a high recurrence rate. Nevertheless, it should be taken into account that our study included only a small number of patients.

Entities:  

Mesh:

Year:  2011        PMID: 21057964     DOI: 10.1007/s00534-010-0341-x

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  7 in total

1.  Two cases of partial hepatectomy for malignant melanoma.

Authors:  Aaron I Karlen; Justin J Clark; Linda L Wong
Journal:  Hawaii J Med Public Health       Date:  2012-04

2.  A 20-year experience of hepatic resection for melanoma: is there an expanding role?

Authors:  Mark B Faries; Anna Leung; Donald L Morton; Danielle Hari; Ji-Hey Lee; Myung-shin Sim; Anton J Bilchik
Journal:  J Am Coll Surg       Date:  2014-05-10       Impact factor: 6.113

Review 3.  Indications, limitations and maneuvers to enable extended hepatectomy: current trends.

Authors:  Dimitrios Dimitroulis; Petros Tsaparas; Serena Valsami; Dimitrios Mantas; Eleftherios Spartalis; Charalampos Markakis; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

4.  Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma.

Authors:  Shun-Da Du; Yi-Lei Mao; Shao-Hua Li; Xin-Ting Sang; Xin Lu; Yi-Yao Xu; Hai-Feng Xu; Lin Zhao; Chun-Mei Bai; Shou-Xian Zhong; Jie-Fu Huang
Journal:  World J Hepatol       Date:  2012-11-27

5.  Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma.

Authors:  Brian A Boone; Samantha Perkins; Rupal Bandi; Ernesto Santos; Kevin McCluskey; David L Bartlett; James F Pingpank
Journal:  J Surg Oncol       Date:  2018-04       Impact factor: 3.454

6.  Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience.

Authors:  Vidhya Karivedu; Ihab Eldessouki; Ahmad Taftaf; Zheng Zhu; Abouelmagd Makramalla; Nagla Abdel Karim
Journal:  Case Rep Oncol Med       Date:  2019-04-17

7.  Liver resection for non-colorectal, non-carcinoid, non-sarcoma metastases: a multicenter study.

Authors:  Guillaume Martel; Jeff Hawel; Janelle Rekman; Kristopher P Croome; Kimberly Bertens; Fady K Balaa; Roberto Hernandez-Alejandro
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.